HomeAI · summaries
Storia in 5 fonti
Daraxonrasib exhibits ‘encouraging signal’ in RAS -mutant metastatic lung cancer
An oral drug widely expected to transform pancreatic cancer treatment has demonstrated encouraging clinical activity in metastatic non-small cell lung cancer. Daraxonrasib (Rasonque, Revolution Medicines) induced durable responses in patients with previously treated, RAS-mutant NSCLC, according to results of a phase 1/phase 2 dose-escalation and dose-expansion study.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
Karmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer
- ·
nature.com
Landmark pancreatic cancer drug shows potential against lung cancer too
Results bolster hopes that the drug daraxonrasib could prove effective against a variety of tumours.
